UCB PHARMA

Active

Public limited companyfounded 1968active for 58 yearsResearchdreef 60, 1070 Anderlecht, Belgium13 active companies are registered at this addressKBO/BCE: BE 0403.096.168

Summary

UCB PHARMA has been active since 1968 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €16.23bn and a net result of €4.24bn, of which €3.82bn non-recurring income. Equity is growing by about 16% per year across the filed financial years. Its solvency ranks better than 84% of 6,158 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Risk analysisFollow Report Compare

UCB PHARMAActiveChecked score 94/100

Risk analysis Report Compare

Directors

4 directors, 2 in day-to-day management, no change since 2026

Board 4

Jean-Christophe Tellier

Director · since 17-03-2014

Current

Caroline Vancoillie

Director · since 09-05-2018

Current

Jacques Marbehant

Director · since 01-07-2026

Current

Charl van Zyl

Director

Current

5 not recently confirmed

Still in office according to the deeds, but no deed of the last six years confirms the mandate. Mandates like this have often ended since, in a deed we have not read yet.

Guido Van Dingenen

Additional director · since 15-03-2005

Not recently confirmed

Philippe Proost

Director · since 15-03-2005

Not recently confirmed

Didier Malherbe

Director · since 21-03-2006

Not recently confirmed

Iris Loëw-Fredrich

Director

Not recently confirmed

Simon Looman

Director

Not recently confirmed

Day-to-day management 2

Geoffroy Folie

Délégué chargé de la gestion journalière · since 19-10-2020

Current

Myriam Juckler

Déléguée chargée de la gestion journalière · since 26-07-2024

Current

2 not recently confirmed

Still in office according to the deeds, but no deed of the last six years confirms the mandate. Mandates like this have often ended since, in a deed we have not read yet.

Didier Malherbe

Managing director · since 27-03-2006

Not recently confirmed

Nicolas Gouwy

Manager qui assurera la gestion journalière · since 16-02-2005

Not recently confirmed

Statutory auditor 1

Mazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRL

Commissaire aux comptes · since 26-08-2024 · permanent representative: Sébastien Schueremans

Current

Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ. See the directors and other office holders in the KBO →

Mandate history

38 people since 2004, 13 in office

All 38 In office 13 Ended 25

Board
Day-to-day management
Statutory auditor
not recently confirmed
began earlier

Mandates per person, with start and end dates
Name	Functions and periods
Jean-Christophe Tellier	Director, from 17-03-2014 to date
Charl van Zyl	Director, from 10-05-2017 to date
Caroline Vancoillie	Director, from 09-05-2018 to date
Jacques Marbehant	Délégué chargé de la gestion journalière, from 22-11-2019 to 26-07-2024 Director, from 01-07-2026 to date
Geoffroy Folie	Délégué chargé de la gestion journalière, from 19-10-2020 to date
Myriam Juckler	Déléguée chargée de la gestion journalière, from 26-07-2024 to date
Mazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRL	Commissaire aux comptes, from 26-08-2024 to date
Guido Van Dingenen	Additional director, from 15-03-2005 not ended, last confirmed 09-05-2005
Philippe Proost	Director, from before 15-03-2005 not ended, last confirmed 09-05-2005
Didier Malherbe	Director, from 21-03-2006 not ended, last confirmed 28-04-2006 Managing director, from 27-03-2006 not ended, last confirmed 28-04-2006
Simon Looman	Director, from before 28-04-2006 not ended, last confirmed 28-04-2006
Iris Loëw-Fredrich	Director, from before 27-05-2011 not ended, last confirmed 27-05-2011
Nicolas Gouwy	Manager qui assurera la gestion journalière, from 16-02-2005 not ended, last confirmed 03-08-2005
Kirsten Lund-Jürgensen	Administrateur additionnel, from 18-07-2019 to 10-09-2026
Forvis Mazars Réviseurs d’Entreprises	Statutory auditor, from 09-07-2021 to 26-08-2024
PwC Réviseurs d'Entreprises SRL	Statutory auditor, from 11-06-2012 to 09-07-2021
Eric Browaeys	Délégué chargé de la gestion journalière, from 01-04-2015 to 19-10-2020
Cleo Ricci	Daily management delegate, from 26-03-2012 to 31-03-2019 Director, from 15-01-2016 to 31-03-2019
Benoit Stevens	Daily management delegate, from 26-03-2012 to 01-04-2018 Director, from 15-01-2016 to 19-04-2018
Fabrice Enderlin	Director, from 13-05-2008 to 10-05-2017
Mark McDade	Director, from before 27-05-2011 to 31-12-2016
Anna S. Richo	Director, from 17-01-2013 to 15-01-2016
Ismail Kola	Director, from 08-12-2009 to 15-01-2016
THIELGEN Detlef	Director, from before 09-05-2012 to 15-01-2016
Jean-Christophe DONCK	Délégué chargé de la gestion journalière, from 01-07-2009 to 01-04-2015
Nunzio Antonelli	Director, from before 27-05-2011 to 31-01-2015
Frédéric Roch Doliveux	Director, until 16-02-2005 Director, from before 09-05-2012 to 17-03-2014 Director, until 17-03-2014
Robert Trainor	Director, from before 09-05-2012 to 01-01-2013
Daniel Goossens	Statutory auditor, from 08-06-2007 to 11-06-2012
Christian Capouillez	Daily management delegate, until 03-05-2012
Iris Löw-Friedrich	Director, from 13-05-2008 to 26-03-2012
François Thys	Délégué chargé de la gestion journalière, until 01-07-2009
William Robinson	Director, until 13-05-2009
Luc Missorten	Director, until 27-08-2008
Jean-Pierre Pradier	Director, until 30-04-2008
Luc Vermeesch	Director, from 16-02-2005 to 28-04-2006 Manager qui assurera la gestion journalière, until 03-08-2005
A. Geeraerts	Director, until 16-07-2004
D. Goossens	Statutory auditor, until 16-07-2004

Show all 38 people Show the first 12See the board, name and registered office on a given date →

Owners and capital

Owners

2 owners

Chain of control

U C B 99.99%
UCB PHARMA

Highest known parent: U C B. The sources do not say who stands above it.

Owners 2

U C Bparent
Sourceown accounts 2025 LEI register accounts U C B 2025

99.99%
UCB Fipar
Sourceown accounts 2025 accounts UCB Fipar 2025

0.01%

According to the 2025 annual accounts of UCB PHARMA and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.

Capital and shareholders

Shareholders according to the deeds

After the capital increase act of 28-07-2022 ↗

UCB €819,225,268.29 in kind

After the capital increase act of 30-12-2020 ↗

The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years

28-07-2022 Capital increase of €819,225,260.40 · to €7,804,773,797.45 · 98,433,814 new shares
22-01-2021 Capital stated in the deed · €6,985,548,537.05 · 839,351,526 shares
30-12-2020 Capital increase of €5,751,269,288.48 · to €6,985,548,537.05
03-05-2019 Capital increase of €305,116,347.97 · to €1,234,279,248.57
11-04-2016 Capital increase of €234,701,369.60 · to €929,162,900.60
04-06-2010 Capital increase of €500,000,000 · to €893,044,625 · “sans création d'actions nouvelles”, “mais par augmentation du pair comptable des actions existantes”
04-06-2010 Capital reduction of €198,583,094 · to €694,461,531 · to absorb losses
15-06-2009 Capital increase of €359,000,000 · to €752,044,625 · “sans création d'actions nouvelles”, “mais par augmentation du pair comptable des actions existantes”

Show 2 older capital entries

15-06-2009 Capital reduction of €359,000,000 · to €393,044,625 · to absorb losses
24-05-2004 Capital stated in the deed · €1,000,000